DOCSLIB.ORG

The Integration of ENCODE Into the Study of the Complexity of Cancer Susceptibility

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

The Integration of ENCODE into the Study of the Complexity of Cancer Susceptibility Stephen J. Chanock, M.D. Director, Division of Cancer Epidemiology & Genetics July 1, 2015 Etiology of Cancer Environment Genetic Susceptibility Mutations SNPs STR’s Lifestyle Chromosomes (Epigenetics) 100% 100% “Triggers” “Set Point” “Chance” Cancer Genomics: 4 Spaces >115 Cancer Syndromes >25 Moderate Penetrant BRCA1/2 >475 GWAS Loci Lynch Syndrome ACMG “AcConable” Germline TEST: Single MutaBon Somatic Heterogeneity Singe Gene Metastases Panel of “Cancer Genes” ‘Drivers’ Exome ‘ Passengers’ Whole Genome TarGeted Therapy HER2 TCGA/ICGC- Discovery Actionable Clinically EGFR Cosmic Data BRAF600 What Happens When There is More than One Genome? ChallenGe of Cancer Genomics TCGA: Driven by the Numbers But not yet validated in the laboratory…. Value of Frequency in Generating Hypotheses 5 But, further laboratory work is needed… Evidence for Heritability of Cancer 1866 Broca observed heritability based on familial breast cancer Interim Twin/Family/Sibling studies… 1969 Li-Fraumeni observed familial clustering (TP53) 1971 Knudson postulated “two-hit” hypothesis for retinoblastoma 1991 Positional cloning of a familial breast cancer gene (BRCA1) >115 Genes Mutated in Cancer Susceptibility Syndromes SDHB Ascertained in Families MUTYH ALK FANCD2 Rare Mutaon with Strong Effect MSH2 VHL MSH6 XPC POT1 FANCL HRAS MLH1 PMS2 FANCF FANCEOncoGenes & Tumor Suppressors BAP1 TERT EGFR CDKN2A MITF WT1 SDHA FANCG DDB2 PHOXB2 POLH PAX5 EXT2 WRN TMEM127 CDK4 GATA2 SBDS NBS1 GALNT12 SDHAF2 PTPN11 HAX1 XPA RET MEN1 TERC BMPR1A ATM SDHC ERCC3 PTCH PTEN MET FANCC SDHD HRPT2 DIS3L2 KIT SUFO CBL PDGFRA APC TSC1 EXT1 RECQL4 T FH FANCB SLX4 TSC2 TP53 ELANE ERCC4 WRAP53 STK11 FANCN/BRIP1 FLCN TINF2 CEBPA RUNX1 BRCA2 NF1 ERCC2 SMARCB1 FANCM BRCA1 CHEK2 RB1 CYLD FANCJ SMAD4 NF2 MAX BUB1B CDH1 RAD51C Incomplete “Penetrance” FANCI FANCA HOXB13 BLM DICER1 ERCC5 Not all affected deVelop cancer GPC3 Modifiers - genec & environmental DKC1 TCGA: Lessons Learned from the Data Survival Analyses Impact of germline or somatic mutations 8 High Penetrance Mutations & Somatic Alterations Nearly 50% “High Frequency” Somac Mutaons Rahman Nature 2014 Search for Common Variants in Complex Diseases Reproducible TechnoloGy SNP Microarray Chip >5 M genotyped SNPs across genome >30 M imputed SNPs across genome High Concordance > 99.5%/assay ‘Markers’ across the genome Commitment to Mapping Creates a mulple tesng problem Published Cancer GWAS Etiology Hits: July 2015 TARDBP FOXQ1 IRF4 PEX14 KIF1B TRIM31 2p25.2 EXOC2 NEDD9 >490 Disease Loci marked by SNPs 1p36 TAF1B RANBP9 1p36 NOL10 GPX6 For > 29 “cancers” PEX14 GABBR1 HLA-A/B/C DDX1 HLA-F RSPO1 ITPR1 6p22.3 BAT3 GRM4 1 Locus marked by a CNV 2p24.1 DAZL MICB 6p22.1 HLA-DQ C2orf43 NCOA1 SLC4A7 EOMES MICA BAK1 20% InterGenic TSPAN32 2p22.2 MAD1L1 TGFBR2 GSDMB 6p21.33 10p15.1 TERT/ DMRT1 LSP1 11p15 THADA EPAS1 CLPTM1L CCHCR1 SP8 ~8% Shared between cancers= Pleiotropy ITGA9 ULK4 TACC3 HLA-DRB5 BNC2 GATA3 NAT2 9p21.3 LMO1 CCND2 REL IRX4 6p21.32 JAZF1 DNAH11 SLC25A37 9p21 FOXP4 NKX3.1 CDKN2A/ 10p14 ATF7IP 1p13.2 CDKN1A CDKN2B HSD17B12 12p13.1 EHBP1 DAB2 PIP4K2A 3p12.1 PRKAA1 NOTCH4 EBF2 DNAJC1 FGF10 HLA-DRA TNS3 FAM111A ITPR2 GSTM1 GGCX/ IKZF1 10p12.31 OR8U8 deletion VAMP8 EXOC1 5p12 ARMC2 3p11.2 HLA-DRB6 EGFR 8p12 NRG1 OVOL1/ PTHLH SNX32 AFM MARCH8 1p11.2 PDE4D DDX4 UNC5CL BTNL2 TUBA1C 1q21.1 ARID5B 11q13 CCND1 ACOXL SIDT1 COX18 MSMB 12q13 12q13.13 GOLPH3L MAP3K1 RAB3C MYO6 PRDM14 PDLIM5 4q22.3 HNF4G ERG2 ZNF365 1q21.3 2q14.2 ZBTB20 >100 to be reported by ONCOARRAY KRT8 KRT5 6q14.1 8q21.11 POLD3 KCNN3 DUSP12 ADH1B LIN28B LMTK2 8q21.13 ZMIZ1 EEFSEC ARRDC3 10q24.2 11q14 DLG2 KITLG RFX6 6q22.1 FOXE1 SLC25A44 ZEB2 TET2 RGS22 FAS 1q22 (Breast/prostate/lung/colon/oVarian8q22.3 ) NTN4 12q23.1 ZBTB38 ECHDC1/ PLCE1 MMP7 TYR RNF146 HACE1 9q31.2 RAD23B STAT4 LEF1 CENP3 POT1 EIF3H UCK2 CLDN11/ TRIM8 10q25.1 ACAD10 ALDH2 3q25.31 11q23.1 ATM SKIL HBS1L DAB21P ITGA6 4q26 SYNPO2 7q32 MYC CCDC26 TCF7L2 CDCA7 VTI1A SCARB1 LGR6 ZC3H11A TERC PHLDB1 HTR3B DLX2 MYNN 5q31.1 PITX1 ESR1 LINC-PINT 2q31.1 8q24 PVT1 ABO 10q26.12 PRLHR MDS1 GRAMD1B CXCR5 TBX5 MDM4 NR5A2 SPRY4 IPCEF1 ARHGEF5 NABP1 ST6GAL1 CTBP2 11q24.3 3q27.3 EBF1 TAB2 ETS1 RPL6 12q24.21 SLC41A1 CASP8 PSCA TP63 ADAM29 RSG17 FGFR2 10q26 LPP 6q25.1 C12orf51 DUSP10 ERBB4 FAM44B C3orf21 BARD1 PARP1 DIRC3 SLC22A3 RHOU SP140 2q35 UGT1A MLPH SHROOM2 FARP2 C20orf54 TGM3 SMG6 VPS53 BABAM1 ELL BMP2 20p12.3 TBX1 TP53 PTPN2 19p13 XAGE3 CEBPE TNFRSF13B JAG1 CHEK2 GREM1 18q11.2 NUDT11 MIPEP TNFRSF19 NKX2-1 ATAD5 NRIP1 CCNE1 RHPN2 EMID1 ZNRF3 TOX3 PAX9 15q15.1 HEATR3 HNF1Bx2 17q12 CHST9 RALY CDC91L1 AR PDX1 MBIP 19q13 GRIK1 BACH1 C19orf61 XBP1 MTMR3 FERMT2 BMF 17q21.32 SLC14A1 BRCA2 FTO HAP1 PRKD2 ADNP RUNX1 SLC7A DCC 22q13 BMP4 CDH1 SPOP MKL1 15q21.3 ZNF652 SMAD7 KLK2/ LAMA5 GATAS TMPRSS2 MCM3AP Xq13 16q22.3 KLK3 CBX7 22q13.1 SIX1 PHLPP2 BRIP1 15q23 COX11 PMAIP1 BCL2 LILRA3 RTEL1 MX2 TFF1 CDYL2 16q23.1 RAD51L1 17q22 22q13 RAD51B BPTF SALL3 ZGPAT 13q22 CHRNA3/5 IRF8 FAM19A5 13q22.1 TTC9 17q24 CPEB1 MC1R UBAC2 CCDC88C 15q25.1 PRC1 Virtually none are associated with outcomes 13 Basal Cell 14 Bladder 85 Breast 7 Cervical 31 CLL 31 Colorectal 1 Endometrial 17 Esophageal Sq 3 Ewing Sarcoma 1 Gallbladder 4 Gastric 10 Glioma 8 Hodgkins 5 Kidney 7 Liver 20 Lung 14 Melanoma 31 Multiple 6 Multiple Myeloma 11 Nasopharyngeal 9 Neuroblastoma 13 Non-Hodgkin 2 Osteosarcoma 16 Ovary 14 Pancreas 9 Pediatric ALL 99 Prostate 21 Testicular 5 Thyroid 3 Wilms GWAS Signals & Somac Mutaons: No Strong Correlaon Redundant Pathways- ‘NOT DriVers’ GWAS Genes Permutation Genes Number of Mutations (per 100 individuals) M Machiela in Revision 0 0−1 1−2 2−3 3−4 4−5 5< Interpretaon: Correlaon does not imply causaon GWAS designs provide no mechanism to disnguish stascal associaon from causaon Linkage GWAS NGS Balding, Nature Genecs Review 2006 Can we use ENCODE to priorize SNPs for follow-up? GPA: A Statistical Approach to Prioritizing GWAS Results by Integrating Pleiotropy and Annotation Comprehensive Functional Annotation of 77 Prostate Dongjun Chung1,2., Can Yang1,3,4., Cong Li5, Joel Gelernter3,6,7,8, Hongyu Zhao1,5,7,9* Cancer Risk Loci 1 Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, United States of America, 2 Department of Public Health Sciences, Medical University Dennis J. Hazelett1*, Suhn Kyong Rhie1, Malaina Gaddis2, Chunli Yan1, Daniel L. Lakeland3, of South Carolina, Charleston, South Carolina, United States of America, 3 Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, United States of 4 5" 6" 5 America, 4 Department of Mathematics, Hong Kong Baptist University, Hong Kong, China, 5 Program in Computational Biology and Bioinformatics, Yale University, New Simon G. Coetzee , Ellipse/GAME-ON consortium , Practical consortium , Brian E. Henderson , Haven, Connecticut, United States of America, 6 VA CT Healthcare Center, West Haven, Connecticut, United States of America, 7 Department of Genetics, Yale School of Houtan Noushmehr4, Wendy Cozen7, Zsofia Kote-Jarai6, Rosalind A. Eeles6,8, Douglas F. Easton9, Medicine, West Haven, Connecticut, United States of America, 8 Department of Neurobiology, Yale School of Medicine, New Haven, Connecticut, United States of America, 5 10 2 1 9 VA Cooperative Studies Program Coordinating Center, West Haven, Connecticut, United States of America Christopher A. Haiman , Wange Lu , Peggy J. Farnham , Gerhard A. Coetzee * 1 Departments of Urology and Preventive Medicine, Norris Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, California, United States of America, 2 Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of Abstract America, 3 Sonny Astani Department of Civil and Environmental Engineering, University of Southern California, Los Angeles, California, United States of America, Results from Genome-Wide Association Studies (GWAS) have shown that complex diseases are often affected by many 4 Department of Genetics, University of Sa˜o Paulo, Ribeira˜o Preto, Brazil, 5 Department of Preventive Medicine, Norris Cancer Center, University of Southern California genetic variants with small or moderate effects. Identifications of these risk variants remain a very challenging problem. Keck School of Medicine, Los Angeles, California, United States of America, 6 The Institute of Cancer Research, Sutton, United Kingdom, 7 USC Keck School of Medicine, There is a need to develop more powerful statistical methods to leverage available information to improve upon traditional Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, United States of America, 8 Royal Marsden National Health Service (NHS) approaches that focus on a single GWAS dataset without incorporating additional data. In this paper, we propose a novel Foundation Trust, London and Sutton, United Kingdom, 9 Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United statistical approach, GPA (Genetic analysis incorporating Pleiotropy and Annotation), to increase statistical power to identify Kingdom, 10 Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, Department of Biochemistry and Molecular Biology, Keck School of Medicine, risk variants through joint analysis of multiple GWAS data sets and annotation information because: (1) accumulating University of Southern California, Los Angeles, California, United States of America evidence suggests that different complex diseases share common risk bases, i.e., pleiotropy; and (2) functionally annotated variants have been consistently demonstrated to be enriched among GWAS hits. GPA can integrate multiple GWAS datasets and functional annotations to seek association signals, and it can also perform hypothesis testing to test the presence of Abstract pleiotropy and enrichment of functional annotation. Statistical inference of the model parameters and SNP ranking is YES achieved through an EM algorithm that can handle genome-wide markers efficiently.
Recommended publications
  • Exceptional Conservation of Horse–Human Gene Order on X Chromosome Revealed by High-Resolution Radiation Hybrid Mapping

    Exceptional Conservation of Horse–Human Gene Order on X Chromosome Revealed by High-Resolution Radiation Hybrid Mapping

    Exceptional conservation of horse–human gene order on X chromosome revealed by high-resolution radiation hybrid mapping Terje Raudsepp*†, Eun-Joon Lee*†, Srinivas R. Kata‡, Candice Brinkmeyer*, James R. Mickelson§, Loren C. Skow*, James E. Womack‡, and Bhanu P. Chowdhary*¶ʈ *Department of Veterinary Anatomy and Public Health, ‡Department of Veterinary Pathobiology, College of Veterinary Medicine, and ¶Department of Animal Science, College of Agriculture and Life Science, Texas A&M University, College Station, TX 77843; and §Department of Veterinary Pathobiology, University of Minnesota, 295f AS͞VM, St. Paul, MN 55108 Contributed by James E. Womack, December 30, 2003 Development of a dense map of the horse genome is key to efforts ciated with the traits, once they are mapped by genetic linkage aimed at identifying genes controlling health, reproduction, and analyses with highly polymorphic markers. performance. We herein report a high-resolution gene map of the The X chromosome is the most conserved mammalian chro- horse (Equus caballus) X chromosome (ECAX) generated by devel- mosome (18, 19). Extensive comparisons of structure, organi- oping and typing 116 gene-specific and 12 short tandem repeat zation, and gene content of this chromosome in evolutionarily -markers on the 5,000-rad horse ؋ hamster whole-genome radia- diverse mammals have revealed a remarkable degree of conser tion hybrid panel and mapping 29 gene loci by fluorescence in situ vation (20–22). Until now, the chromosome has been best hybridization. The human X chromosome sequence was used as a studied in humans and mice, where the focus of research has template to select genes at 1-Mb intervals to develop equine been the intriguing patterns of X inactivation and the involve- orthologs.
  • Structure and Function of the Human Recq DNA Helicases

    Structure and Function of the Human Recq DNA Helicases

    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2005 Structure and function of the human RecQ DNA helicases Garcia, P L Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-34420 Dissertation Published Version Originally published at: Garcia, P L. Structure and function of the human RecQ DNA helicases. 2005, University of Zurich, Faculty of Science. Structure and Function of the Human RecQ DNA Helicases Dissertation zur Erlangung der naturwissenschaftlichen Doktorw¨urde (Dr. sc. nat.) vorgelegt der Mathematisch-naturwissenschaftlichen Fakultat¨ der Universitat¨ Z ¨urich von Patrick L. Garcia aus Unterseen BE Promotionskomitee Prof. Dr. Josef Jiricny (Vorsitz) Prof. Dr. Ulrich H ¨ubscher Dr. Pavel Janscak (Leitung der Dissertation) Z ¨urich, 2005 For my parents ii Summary The RecQ DNA helicases are highly conserved from bacteria to man and are required for the maintenance of genomic stability. All unicellular organisms contain a single RecQ helicase, whereas the number of RecQ homologues in higher organisms can vary. Mu- tations in the genes encoding three of the five human members of the RecQ family give rise to autosomal recessive disorders called Bloom syndrome, Werner syndrome and Rothmund-Thomson syndrome. These diseases manifest commonly with genomic in- stability and a high predisposition to cancer. However, the genetic alterations vary as well as the types of tumours in these syndromes. Furthermore, distinct clinical features are observed, like short stature and immunodeficiency in Bloom syndrome patients or premature ageing in Werner Syndrome patients. Also, the biochemical features of the human RecQ-like DNA helicases are diverse, pointing to different roles in the mainte- nance of genomic stability.
  • Open Full Page

    Open Full Page

    CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders Michael F. Walsh1, Vivian Y. Chang2, Wendy K. Kohlmann3, Hamish S. Scott4, Christopher Cunniff5, Franck Bourdeaut6, Jan J. Molenaar7, Christopher C. Porter8, John T. Sandlund9, Sharon E. Plon10, Lisa L. Wang10, and Sharon A. Savage11 Abstract DNA repair syndromes are heterogeneous disorders caused by around the world to discuss and develop cancer surveillance pathogenic variants in genes encoding proteins key in DNA guidelines for children with cancer-prone disorders. Herein, replication and/or the cellular response to DNA damage. The we focus on the more common of the rare DNA repair dis- majority of these syndromes are inherited in an autosomal- orders: ataxia telangiectasia, Bloom syndrome, Fanconi ane- recessive manner, but autosomal-dominant and X-linked reces- mia, dyskeratosis congenita, Nijmegen breakage syndrome, sive disorders also exist. The clinical features of patients with DNA Rothmund–Thomson syndrome, and Xeroderma pigmento- repair syndromes are highly varied and dependent on the under- sum. Dedicated syndrome registries and a combination of lying genetic cause. Notably, all patients have elevated risks of basic science and clinical research have led to important in- syndrome-associated cancers, and many of these cancers present sights into the underlying biology of these disorders. Given the in childhood. Although it is clear that the risk of cancer is rarity of these disorders, it is recommended that centralized increased, there are limited data defining the true incidence of centers of excellence be involved directly or through consulta- cancer and almost no evidence-based approaches to cancer tion in caring for patients with heritable DNA repair syn- surveillance in patients with DNA repair disorders.
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model

    Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model

    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
  • ONCOPANEL (Popv3)

    ONCOPANEL (Popv3)

    ONCOPANEL (POPv3) TEST INFORMATION BACKGROUND: Somatic genetic alterations in oncogenes and tumor-suppressor genes contribute to the pathogenesis and evolution of human cancers. These alterations can provide prognostic and predictive information and stratify cancers for targeted therapeutic information. We classify these alterations into five tiers using the following guidelines: Tier 1: The alteration has well-established published evidence confirming clinical utility in this tumor type, in at least one of the following contexts: predicting response to treatment with an FDA-approved therapy; assessing prognosis; establishing a definitive diagnosis; or conferring an inherited increased risk of cancer to this patient and family. Tier 2: The alteration may have clinical utility in at least one of the following contexts: selection of an investigational therapy in clinical trials for this cancer type; limited evidence of prognostic association; supportive of a specific diagnosis; proven association of response to treatment with an FDA-approved therapy in a different type of cancer; or similar to a different mutation with a proven association with response to treatment with an FDA-approved therapyin this type of cancer. Tier 3: The alteration is of uncertain clinical utility, but may have a role as suggested by at least one of the following: demonstration of association with response to treatment in this cancer type in preclinical studies (e.g., in vitro studies or animal models); alteration in a biochemical pathway that has other known, therapeutically-targetable alterations; alteration in a highly conserved region of the protein predicted, in silico, to alter protein function; or selection of an investigational therapy for a different cancer type.
  • Dietary Chemoprevention Studies in Preclinical Models of Prostate Cancer: Bioactive Lipids and Vitamin D

    Dietary Chemoprevention Studies in Preclinical Models of Prostate Cancer: Bioactive Lipids and Vitamin D

    Dietary Chemoprevention Studies in Preclinical Models of Prostate Cancer: Bioactive Lipids and Vitamin D. Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Justin Bruce Smolinski, B.S. Ohio State University Nutrition (OSUN) Graduate Program The Ohio State University 2010 Dissertation Committee: Professor Steven K. Clinton, Advisor Professor Charles L. Brooks Professor Kichoon Lee Professor Mark L. Failla i Copyright by Justin Bruce Smolinski 2010 ii ABSTRACT Epidemiological evidence suggests that prostate cancer can be modulated by diet. Data exists that implicate both bioactive lipids and the vitamin D/ calcium axis in prostate cancer pathogenesis. These data suggest that bioactive lipids such as omega-3 fatty acids protect against prostate cancer, whereas omega-6 fatty acids promote prostate cancer. Population studies also indicate that a diet high in vitamin D decreases prostate cancer risk while calcium increases risk for prostate cancer, possibly by lowering circulating levels of protective vitamin D. In contrast, recent epidemiological studies indicate that vitamin D does not protect against prostate cancer, indicating that the role of vitamin D and calcium in this disease process is far from established. Importantly, crucial animal experiments are lacking that may serve to provide mechanistic data for the roles of these nutrients. The objective of the first study conducted in this dissertation was to evaluate and compare prostate carcinogenesis in murine models that utilize the SV40 Tag transformation system- TRAMP and Apt121/Rbf. These are commonly used models in prostate cancer chemoprevention studies. We characterized these models with respect to time to tumor development, tumor size and metastasis.
  • Pdf Sub-Classification of Patients with a Molecular Alteration Provides Better Response [57]

    Pdf Sub-Classification of Patients with a Molecular Alteration Provides Better Response [57]

    Theranostics 2021, Vol. 11, Issue 12 5759 Ivyspring International Publisher Theranostics 2021; 11(12): 5759-5777. doi: 10.7150/thno.57659 Research Paper Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation Qin He1, Wenjie Huang2, Danfei Liu1, Tongyue Zhang1, Yijun Wang1, Xiaoyu Ji1, Meng Xie1, Mengyu Sun1, Dean Tian1, Mei Liu1, Limin Xia1 1. Department of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China. 2. Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases; Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Clinical Medicine Research Center for Hepatic Surgery of Hubei Province; Key Laboratory of Organ Transplantation, Ministry of Education and Ministry of Public Health, Wuhan, Hubei, 430030, China. Corresponding author: Dr. Limin Xia, Department of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China; Phone: 86 27 6937 8507; Fax: 86 27 8366 2832; E-mail: [email protected]. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2020.12.29; Accepted: 2021.03.17; Published: 2021.03.31 Abstract Background: Since metastasis remains the main reason for HCC-associated death, a better understanding of molecular mechanism underlying HCC metastasis is urgently needed.
  • Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K

    Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K

    www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1.
  • Supplementary Figure S4

    Supplementary Figure S4

    18DCIS 18IDC Supplementary FigureS4 22DCIS 22IDC C D B A E (0.77) (0.78) 16DCIS 14DCIS 28DCIS 16IDC 28IDC (0.43) (0.49) 0 ADAMTS12 (p.E1469K) 14IDC ERBB2, LASP1,CDK12( CCNE1 ( NUTM2B SDHC,FCGR2B,PBX1,TPR( CD1D, B4GALT3, BCL9, FLG,NUP21OL,TPM3,TDRD10,RIT1,LMNA,PRCC,NTRK1 0 ADAMTS16 (p.E67K) (0.67) (0.89) (0.54) 0 ARHGEF38 (p.P179Hfs*29) 0 ATG9B (p.P823S) (0.68) (1.0) ARID5B, CCDC6 CCNE1, TSHZ3,CEP89 CREB3L2,TRIM24 BRAF, EGFR (7p11); 0 ABRACL (p.R35H) 0 CATSPER1 (p.P152H) 0 ADAMTS18 (p.Y799C) 19q12 0 CCDC88C (p.X1371_splice) (0) 0 ADRA1A (p.P327L) (10q22.3) 0 CCNF (p.D637N) −4 −2 −4 −2 0 AKAP4 (p.G454A) 0 CDYL (p.Y353Lfs*5) −4 −2 Log2 Ratio Log2 Ratio −4 −2 Log2 Ratio Log2 Ratio 0 2 4 0 2 4 0 ARID2 (p.R1068H) 0 COL27A1 (p.G646E) 0 2 4 0 2 4 2 EDRF1 (p.E521K) 0 ARPP21 (p.P791L) ) 0 DDX11 (p.E78K) 2 GPR101, p.A174V 0 ARPP21 (p.P791T) 0 DMGDH (p.W606C) 5 ANP32B, p.G237S 16IDC (Ploidy:2.01) 16DCIS (Ploidy:2.02) 14IDC (Ploidy:2.01) 14DCIS (Ploidy:2.9) -3 -2 -1 -3 -2 -1 -3 -2 -1 -3 -2 -1 -3 -2 -1 -3 -2 -1 Log Ratio Log Ratio Log Ratio Log Ratio 12DCIS 0 ASPM (p.S222T) Log Ratio Log Ratio 0 FMN2 (p.G941A) 20 1 2 3 2 0 1 2 3 2 ERBB3 (p.D297Y) 2 0 1 2 3 20 1 2 3 0 ATRX (p.L1276I) 20 1 2 3 2 0 1 2 3 0 GALNT18 (p.F92L) 2 MAPK4, p.H147Y 0 GALNTL6 (p.E236K) 5 C11orf1, p.Y53C (10q21.2); 0 ATRX (p.R1401W) PIK3CA, p.H1047R 28IDC (Ploidy:2.0) 28DCIS (Ploidy:2.0) 22IDC (Ploidy:3.7) 22DCIS (Ploidy:4.1) 18IDC (Ploidy:3.9) 18DCIS (Ploidy:2.3) 17q12 0 HCFC1 (p.S2025C) 2 LCMT1 (p.S34A) 0 ATXN7L2 (p.X453_splice) SPEN, p.P677Lfs*13 CBFB 1 2 3 4 5 6 7 8 9 10 11
  • Fanconi Anemia, Bloom Syndrome and Breast Cancer

    Fanconi Anemia, Bloom Syndrome and Breast Cancer

    A multiprotein complex in DNA damage response network of Fanconi anemia, Bloom syndrome and Breast cancer Weidong Wang Lab of Genetics, NIA A Multi-protein Complex Connects Two Genomic Instability Diseases: Bloom Syndrome and Fanconi Anemia Bloom Syndrome . Genomic Instability: -sister-chromatid exchange . Cancer predisposition . Mutation in BLM, a RecQ DNA Helicase . BLM participates in: HR-dependent DSB repair Recovery of stalled replication forks . BLM works with Topo IIIa and RMI to Suppress crossover recombination Courtesy of Dr. Ian Hickson A Multi-protein Complex Connects Two Genomic Instability Diseases: Bloom Syndrome and Fanconi Anemia P I l o r t n o BLM IP kDa C HeLa BLAP 250 Nuclear Extract 200- BLM* FANCA* 116- TOPO IIIα* 97- BLAP 100 MLH1* BLM IP BLAP 75 * 66- RPA 70 IgG H 45- * 30- RPA32 IgG L 20- * 12- RPA14 Meetei et al. MCB 2003 A Multi-protein Complex Connects Two Genomic Instability Diseases: Bloom Syndrome and Fanconi Anemia P I A C N A F BLM IP HeLa FANCM= FAAP 250 BLAP 250 Nuclear Extract BLM* BLM* * FANCA* FANCA TOPO IIIα* TOPO IIIα* FAAP 100 BLAP 100 FANCB= FAAP 95 MLH1 FANCA IP BLM IP BLAP 75 BLAP 75 RPA70*/FANCG* RPA 70* FANCC*/FANCE* IgG H FANCL= FAAP 43 FANCF* RPA32* IgG L Meetei et al. MCB 2003 Meetei et al. Nat Genet. 2003, 2004, 2005 BRAFT-a Multisubunit Machine that Maintains Genome Stability and is defective in Fanconi anemia and Bloom syndrome BRAFT Super-complex Fanconi Anemia Bloom Syndrome Core Complex Complex 12 polypeptides 7 polypeptides FANCA BLM Helicase (HJ, fork, D-loop), fork FANCC regression, dHJ dissolution Topo IIIα Topoisomerase, FANCE dHJ dissolution FANCF BLAP75 RMI1 FANCG Stimulates dHJ dissolution.
  • HEREDITARY CANCER PANELS Part I

    HEREDITARY CANCER PANELS Part I

    Pathology and Laboratory Medicine Clinic Building, K6, Core Lab, E-655 2799 W. Grand Blvd. HEREDITARY CANCER PANELS Detroit, MI 48202 855.916.4DNA (4362) Part I- REQUISITION Required Patient Information Ordering Physician Information Name: _________________________________________________ Gender: M F Name: _____________________________________________________________ MRN: _________________________ DOB: _______MM / _______DD / _______YYYY Address: ___________________________________________________________ ICD10 Code(s): _________________/_________________/_________________ City: _______________________________ State: ________ Zip: __________ ICD-10 Codes are required for billing. When ordering tests for which reimbursement will be sought, order only those tests that are medically necessary for the diagnosis and treatment of the patient. Phone: _________________________ Fax: ___________________________ Billing & Collection Information NPI: _____________________________________ Patient Demographic/Billing/Insurance Form is required to be submitted with this form. Most genetic testing requires insurance prior authorization. Due to high insurance deductibles and member policy benefits, patients may elect to self-pay. Call for more information (855.916.4362) Bill Client or Institution Client Name: ______________________________________________________ Client Code/Number: _____________ Bill Insurance Prior authorization or reference number: __________________________________________ Patient Self-Pay Call for pricing and payment options Toll
  • Health-Relevant Phenotypes in the Offspring of Mice Given CAR Activators Prior to Pregnancy S

    Health-Relevant Phenotypes in the Offspring of Mice Given CAR Activators Prior to Pregnancy S

    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2018/08/28/dmd.118.082925.DC1 1521-009X/46/11/1827–1835$35.00 https://doi.org/10.1124/dmd.118.082925 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 46:1827–1835, November 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Health-Relevant Phenotypes in the Offspring of Mice Given CAR Activators Prior to Pregnancy s Karin Dietrich, Jan Baumgart, Leonid Eshkind, Lea Reuter, Ute Gödtel-Armbrust, Elke Butt, Michael Musheev, Federico Marini, Piyush More, Tanja Grosser, Christof Niehrs, Leszek Wojnowski, and Marianne Mathäs Department of Pharmacology (K.D., L.R., U.G.-A., P.M., T.G., L.W., M.Ma.) and Institute of Medical Biostatistics, Epidemiology and Informatics (F.M.), University Medical Center Mainz, Mainz, Germany; Translational Animal Research Center (J.B., L.E.), University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany; Institute of Experimental Biomedicine II, University Hospital Würzburg, Würzburg, Germany (E.B.); Institute of Molecular Biology, Mainz, Germany (M.Mu., C.N.); and Division of Molecular Embryology, German Cancer Research Center (DKFZ-ZMBH Alliance), Heidelberg, Germany (C.N.) Received June 6, 2018; accepted August 22, 2018 Downloaded from ABSTRACT Hepatic induction in response to drugs and environmental chem- analyses. The important environmental pollutant PCB153 acti- icals affects drug therapies and energy metabolism. We investigated vated CAR in the F1 generation in a manner similar to TCPOBOP. whether the induction is transmitted to the offspring. We injected Our findings indicate that chemicals accumulating and persisting 3-day- and 6-week-old F0 female mice with TCPOBOP, an activator in adipose tissue may exert liver-mediated, health-relevant effects dmd.aspetjournals.org of the nuclear receptor constitutive androstane receptor (CAR, on F1 offspring simply via physical transmission in milk.